Global Neoantigen Cancer Vaccine Market Size, Share, Trend and Forecast 2026 | TechSci Research

1
2020 2026
Global Neoantigen Cancer Vaccine Market
FORECAST AND OPPORTUNITIES
www.techsciresearch.com
MARKET INTELLIGENCE . CONSULTING
2

• Table of Contents

S. No. Contents Contents Contents
1. Product Overview Product Overview Product Overview
2. Research Methodology Research Methodology Research Methodology
3. Clinical Trial Analysis Clinical Trial Analysis Clinical Trial Analysis
4. Executive Summary Executive Summary Executive Summary
5. Global Neoantigen Cancer Vaccine Market Outlook Global Neoantigen Cancer Vaccine Market Outlook Global Neoantigen Cancer Vaccine Market Outlook
5.1. Market Size Forecast Market Size Forecast
5.1.1. By Value Volume
5.2. Market Share Forecast Market Share Forecast
5.2.1. By Product (Personalized Neo-antigen Vaccine, Off-the Shelf Neoantigen Vaccine)
5.2.2. By Neoantigen Type (Synthetic Long Peptide (SLP), Nucleic Acid, Dendritic Cell and Tumor Cell) By Neoantigen Type (Synthetic Long Peptide (SLP), Nucleic Acid, Dendritic Cell and Tumor Cell)
5.2.3. By Route of Administration (Intravenous, Intramuscular, Transdermal, Others)
5.2.4. By Cell (Autologous, Allogenic) By Cell (Autologous, Allogenic)
5.2.5. By Technology (RNA Sequencing, Whole Genome Sequencing, HLA Typing) By Technology (RNA Sequencing, Whole Genome Sequencing, HLA Typing)
5.2.6. By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene Gun and Others) By Delivery Mechanism (Liposomes, Virosomes, Electroporation, Gene Gun and Others)
5.2.7. By Application (Lung, Melanoma, Gastrointestinal, Brain Cancer, and Others)
5.2.8. By Company (2023)
5.2.9. By Region
5.3. Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index
6. North America Neoantigen Cancer Vaccine Market Outlook North America Neoantigen Cancer Vaccine Market Outlook North America Neoantigen Cancer Vaccine Market Outlook North America Neoantigen Cancer Vaccine Market Outlook
6.1. Market Size Forecast Market Size Forecast Market Size Forecast
6.1.1. By Value Volume By Value Volume
3

• Table of Contents

S. No. Contents Contents Contents Contents Contents
6.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
6.2.1. By Product By Product By Product
6.2.2. By Neoantigen Type By Neoantigen Type By Neoantigen Type
6.2.3. By Route of Administration By Route of Administration By Route of Administration
6.2.4. By Cell By Cell By Cell
6.2.5. By Technology By Technology By Technology
6.2.6. By Application By Application By Application
6.2.7. By Country By Country By Country
6.3. Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index
6.4. North America Country Analysis North America Country Analysis North America Country Analysis North America Country Analysis
6.4.1. United States Neoantigen Cancer Vaccine Market Outlook United States Neoantigen Cancer Vaccine Market Outlook United States Neoantigen Cancer Vaccine Market Outlook
6.4.1.1. Market Size Forecast Market Size Forecast
6.4.1.1.1. By Value
6.4.1.2. Market Share Forecast Market Share Forecast
6.4.1.2.1. By Product
6.4.1.2.2. By Neoantigen Type
6.4.1.2.3. By Route of Administration
6.4.1.2.4. By Cell
6.4.1.2.5. By Technology
6.4.1.2.6. By Application
6.4.2. Canada Neoantigen Cancer Vaccine Market Outlook Canada Neoantigen Cancer Vaccine Market Outlook Canada Neoantigen Cancer Vaccine Market Outlook
4

• Table of Contents

S. No. Contents Contents Contents Contents Contents
6.4.2.1. Market Size Forecast Market Size Forecast
6.4.2.1.1. By Value
6.4.2.2. Market Share Forecast Market Share Forecast
6.4.2.2.1. By Product
6.4.2.2.2. By Neoantigen Type
6.4.2.2.3. By Route of Administration
6.4.2.2.4. By Cell
6.4.2.2.5. By Technology
6.4.2.2.6. By Application
6.4.3. Mexico Neoantigen Cancer Vaccine Market Outlook Mexico Neoantigen Cancer Vaccine Market Outlook Mexico Neoantigen Cancer Vaccine Market Outlook
6.4.3.1. Market Size Forecast Market Size Forecast
6.4.3.1.1. By Value
6.4.3.2. Market Share Forecast Market Share Forecast
6.4.3.2.1. By Product
6.4.3.2.2. By Neoantigen Type
6.4.3.2.3. By Route of Administration
6.4.3.2.4. By Cell
6.4.3.2.5. By Technology
6.4.3.2.6. By Application
7. Europe Neoantigen Cancer Vaccine Market Outlook Europe Neoantigen Cancer Vaccine Market Outlook Europe Neoantigen Cancer Vaccine Market Outlook Europe Neoantigen Cancer Vaccine Market Outlook Europe Neoantigen Cancer Vaccine Market Outlook
5

• Table of Contents

S. No. Contents Contents Contents Contents Contents
7.1. Market Size Forecast Market Size Forecast Market Size Forecast
7.1.1. By Value Volume By Value Volume
7.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
7.2.1. By Product By Product By Product
7.2.2. By Neoantigen Type By Neoantigen Type By Neoantigen Type
7.2.3. By Route of Administration By Route of Administration By Route of Administration
7.2.4. By Cell By Cell By Cell
7.2.5. By Technology By Technology By Technology
7.2.6. By Application By Application By Application
7.2.7. By Country By Country By Country
7.3. Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index
7.4. Europe Country Analysis Europe Country Analysis Europe Country Analysis Europe Country Analysis
7.4.1. Germany Neoantigen Cancer Vaccine Market Outlook Germany Neoantigen Cancer Vaccine Market Outlook Germany Neoantigen Cancer Vaccine Market Outlook
7.4.1.1. Market Size Forecast Market Size Forecast
7.4.1.1.1. By Value
7.4.1.2. Market Share Forecast Market Share Forecast
7.4.1.2.1. By Product
7.4.1.2.2. By Neoantigen Type
7.4.1.2.3. By Route of Administration
7.4.1.2.4. By Cell
7.4.1.2.5. By Technology
7.4.1.2.6. By Application

6

• Table of Contents

S. No. Contents Contents Contents Contents Contents
7.4.2. France Neoantigen Cancer Vaccine Market Outlook France Neoantigen Cancer Vaccine Market Outlook France Neoantigen Cancer Vaccine Market Outlook
7.4.2.1. Market Size Forecast Market Size Forecast
7.4.2.1.1. By Value
7.4.2.2. Market Share Forecast Market Share Forecast
7.4.2.2.1. By Product
7.4.2.2.2. By Neoantigen Type
7.4.2.2.3. By Route of Administration
7.4.2.2.4. By Cell
7.4.2.2.5. By Technology
7.4.2.2.6. By Application
7.4.3. United Kingdom Neoantigen Cancer Vaccine Market Outlook United Kingdom Neoantigen Cancer Vaccine Market Outlook United Kingdom Neoantigen Cancer Vaccine Market Outlook
7.4.3.1. Market Size Forecast Market Size Forecast
7.4.3.1.1. By Value
7.4.3.2. Market Share Forecast Market Share Forecast
7.4.3.2.1. By Product
7.4.3.2.2. By Neoantigen Type
7.4.3.2.3. By Route of Administration
7.4.3.2.4. By Cell
7.4.3.2.5. By Technology
7.4.3.2.6. By Application
7

• Table of Contents

S. No. Contents Contents Contents Contents Contents
7.4.4. Italy Neoantigen Cancer Vaccine Market Outlook Italy Neoantigen Cancer Vaccine Market Outlook Italy Neoantigen Cancer Vaccine Market Outlook
7.4.4.1. Market Size Forecast Market Size Forecast
7.4.4.1.1. By Value
7.4.4.2. Market Share Forecast Market Share Forecast
7.4.4.2.1. By Product
7.4.4.2.2. By Neoantigen Type
7.4.4.2.3. By Route of Administration
7.4.4.2.4. By Cell
7.4.4.2.5. By Technology
7.4.4.2.6. By Application
7.4.5. Spain Neoantigen Cancer Vaccine Market Outlook Spain Neoantigen Cancer Vaccine Market Outlook Spain Neoantigen Cancer Vaccine Market Outlook
7.4.5.1. Market Size Forecast Market Size Forecast
7.4.5.1.1. By Value
7.4.5.2. Market Share Forecast Market Share Forecast
7.4.5.2.1. By Product
7.4.5.2.2. By Neoantigen Type
7.4.5.2.3. By Route of Administration
7.4.5.2.4. By Cell
7.4.5.2.5. By Technology
7.4.5.2.6. By Application
8

• Table of Contents

S. No. Contents Contents Contents Contents Contents
8. APAC Neoantigen Cancer Vaccine Market Outlook APAC Neoantigen Cancer Vaccine Market Outlook APAC Neoantigen Cancer Vaccine Market Outlook APAC Neoantigen Cancer Vaccine Market Outlook APAC Neoantigen Cancer Vaccine Market Outlook
8.1. Market Size Forecast Market Size Forecast Market Size Forecast
8.1.1. By Value Volume By Value Volume
8.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
8.2.1. By Product By Product By Product
8.2.2. By Neoantigen Type By Neoantigen Type By Neoantigen Type
8.2.3. By Route of Administration By Route of Administration By Route of Administration
8.2.4. By Cell By Cell By Cell
8.2.5. By Technology By Technology By Technology
8.2.6. By Application By Application By Application
8.2.7. By Country By Country By Country
8.3. Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index
8.4. APAC Country Analysis APAC Country Analysis APAC Country Analysis APAC Country Analysis
8.4.1. China Neoantigen Cancer Vaccine Market Outlook China Neoantigen Cancer Vaccine Market Outlook China Neoantigen Cancer Vaccine Market Outlook
8.4.1.1. Market Size Forecast Market Size Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share Forecast Market Share Forecast
8.4.1.2.1. By Product
8.4.1.2.2. By Neoantigen Type
8.4.1.2.3. By Route of Administration
8.4.1.2.4. By Cell
8.4.1.2.5. By Technology
8.4.1.2.6. By Application

9

• Table of Contents

S. No. Contents Contents Contents Contents Contents
8.4.2. India Neoantigen Cancer Vaccine Market Outlook India Neoantigen Cancer Vaccine Market Outlook India Neoantigen Cancer Vaccine Market Outlook
8.4.2.1. Market Size Forecast Market Size Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share Forecast Market Share Forecast
8.4.2.2.1. By Product
8.4.2.2.2. By Neoantigen Type
8.4.2.2.3. By Route of Administration
8.4.2.2.4. By Cell
8.4.2.2.5. By Technology
8.4.2.2.6. By Application
8.4.3. Japan Neoantigen Cancer Vaccine Market Outlook Japan Neoantigen Cancer Vaccine Market Outlook Japan Neoantigen Cancer Vaccine Market Outlook
8.4.3.1. Market Size Forecast Market Size Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share Forecast Market Share Forecast
8.4.3.2.1. By Product
8.4.3.2.2. By Neoantigen Type
8.4.3.2.3. By Route of Administration
8.4.3.2.4. By Cell
8.4.3.2.5. By Technology
8.4.3.2.6. By Application
10

• Table of Contents

S. No. Contents Contents Contents Contents Contents
8.4.4. Australia Neoantigen Cancer Vaccine Market Outlook Australia Neoantigen Cancer Vaccine Market Outlook Australia Neoantigen Cancer Vaccine Market Outlook
8.4.4.1. Market Size Forecast Market Size Forecast
8.4.4.1.1. By Value
8.4.4.2. Market Share Forecast Market Share Forecast
8.4.4.2.1. By Product
8.4.4.2.2. By Neoantigen Type
8.4.4.2.3. By Route of Administration
8.4.4.2.4. By Cell
8.4.4.2.5. By Technology
8.4.4.2.6. By Application
8.4.5. South Korea Neoantigen Cancer Vaccine Market Outlook South Korea Neoantigen Cancer Vaccine Market Outlook South Korea Neoantigen Cancer Vaccine Market Outlook
8.4.5.1. Market Size Forecast Market Size Forecast
8.4.5.1.1. By Value
8.4.5.2. Market Share Forecast Market Share Forecast
8.4.5.2.1. By Product
8.4.5.2.2. By Neoantigen Type
8.4.5.2.3. By Route of Administration
8.4.5.2.4. By Cell
8.4.5.2.5. By Technology
8.4.5.2.6. By Application
11

• Table of Contents

S. No. Contents Contents Contents Contents Contents
8.4.6. Singapore Neoantigen Cancer Vaccine Market Outlook Singapore Neoantigen Cancer Vaccine Market Outlook Singapore Neoantigen Cancer Vaccine Market Outlook
8.4.6.1. Market Size Forecast Market Size Forecast
8.4.6.1.1. By Value
8.4.6.2. Market Share Forecast Market Share Forecast
8.4.6.2.1. By Product
8.4.5.2.2. By Neoantigen Type
8.4.6.2.3. By Route of Administration
8.4.6.2.4. By Cell
8.4.6.2.5. By Technology
8.4.6.2.6. By Application
9. South America Neoantigen Cancer Vaccine Market Outlook South America Neoantigen Cancer Vaccine Market Outlook South America Neoantigen Cancer Vaccine Market Outlook South America Neoantigen Cancer Vaccine Market Outlook South America Neoantigen Cancer Vaccine Market Outlook
9.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
9.1.1. By Value Volume By Value Volume By Value Volume
9.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
9.2.1. By Product By Product By Product
9.2.2. By Neoantigen Type By Neoantigen Type By Neoantigen Type
9.2.3. By Route of Administration By Route of Administration By Route of Administration
9.2.4. By Cell By Cell By Cell
9.2.5. By Technology By Technology By Technology
12

• Table of Contents

S. No. Contents Contents Contents Contents Contents
9.2.6. By Application By Application By Application
9.2.7. By Country By Country By Country
9.3. Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index
9.4. South America Country Analysis South America Country Analysis South America Country Analysis South America Country Analysis
9.4.1. Brazil Neoantigen Cancer Vaccine Market Outlook Brazil Neoantigen Cancer Vaccine Market Outlook Brazil Neoantigen Cancer Vaccine Market Outlook
9.4.1.1. Market Size Forecast Market Size Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share Forecast Market Share Forecast
9.4.1.2.1. By Product
9.4.1.2.2. By Neoantigen Type
9.4.1.2.3. By Route of Administration
9.4.1.2.4. By Cell
9.4.1.2.5. By Technology
9.4.1.2.6. By Application
9.4.2. Argentina Neoantigen Cancer Vaccine Market Outlook Argentina Neoantigen Cancer Vaccine Market Outlook Argentina Neoantigen Cancer Vaccine Market Outlook
9.4.2.1. Market Size Forecast Market Size Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share Forecast Market Share Forecast
9.4.2.2.1. By Product
13

• Table of Contents

S. No. Contents Contents Contents Contents Contents
9.4.2.2.2. By Neoantigen Type
9.4.2.2.3. By Route of Administration
9.4.2.2.4. By Cell
9.4.2.2.5. By Technology
9.4.2.2.6. By Application
9.4.3. Colombia Neoantigen Cancer Vaccine Market Outlook Colombia Neoantigen Cancer Vaccine Market Outlook Colombia Neoantigen Cancer Vaccine Market Outlook Colombia Neoantigen Cancer Vaccine Market Outlook
9.4.3.1. Market Size Forecast Market Size Forecast Market Size Forecast
9.4.3.1.1. By Value By Value
9.4.3.2. Market Share Forecast Market Share Forecast Market Share Forecast
9.4.3.2.1. By Product
9.3.3.2.2. By Neoantigen Type
9.4.3.2.3. By Route of Administration
9.4.3.2.4. By Cell
9.4.3.2.5. By Technology
9.4.3.2.6. By Application
10. Middle East Africa Neoantigen Cancer Vaccine Market Outlook Middle East Africa Neoantigen Cancer Vaccine Market Outlook Middle East Africa Neoantigen Cancer Vaccine Market Outlook Middle East Africa Neoantigen Cancer Vaccine Market Outlook Middle East Africa Neoantigen Cancer Vaccine Market Outlook Middle East Africa Neoantigen Cancer Vaccine Market Outlook
10.1. Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast Market Size Forecast
10.1.1. By Value Volume By Value Volume By Value Volume By Value Volume
10.2. Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast Market Share Forecast
10.2.1. By Product By Product By Product By Product
10.2.2. By Neoantigen Type By Neoantigen Type By Neoantigen Type By Neoantigen Type
10.2.3. By Route of Administration By Route of Administration By Route of Administration By Route of Administration
14

• Table of Contents

S. No. Contents Contents Contents Contents Contents Contents Contents Contents Contents
10.2.4. By Cell By Cell By Cell By Cell
10.2.5. By Technology By Technology By Technology By Technology
10.2.6. By Application By Application By Application By Application
10.2.7. By Country By Country By Country By Country
10.3. Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index Market Attractiveness Index
10.4 Middle East Africa Country Analysis Middle East Africa Country Analysis Middle East Africa Country Analysis Middle East Africa Country Analysis Middle East Africa Country Analysis
10.4.1. South Africa Neoantigen Cancer Vaccine Market Outlook South Africa Neoantigen Cancer Vaccine Market Outlook South Africa Neoantigen Cancer Vaccine Market Outlook South Africa Neoantigen Cancer Vaccine Market Outlook
10.4.1.1. Market Size Forecast Market Size Forecast Market Size Forecast
10.4.1.1.1. By Value By Value
10.4.1.2. Market Share Forecast Market Share Forecast Market Share Forecast
10.4.1.2.1. 10.4.1.2.1. By Product
10.4.1.2.2. 10.4.1.2.2. By Neoantigen Type
10.4.1.2.3. 10.4.1.2.3. By Route of Administration
10.4.1.2.4. 10.4.1.2.4. By Cell
10.4.1.2.5. 10.4.1.2.5. By Technology
10.4.1.2.6. 10.4.1.2.6. By Application
10.4.2. Saudi Arabia Neoantigen Cancer Vaccine Market Outlook Saudi Arabia Neoantigen Cancer Vaccine Market Outlook Saudi Arabia Neoantigen Cancer Vaccine Market Outlook Saudi Arabia Neoantigen Cancer Vaccine Market Outlook
10.4.2.1. Market Size Forecast Market Size Forecast Market Size Forecast
10.4.2.1.1. By Value By Value
10.4.2.2. Market Share Forecast Market Share Forecast Market Share Forecast
10.4.2.2.1. 10.4.2.2.1. By Product
10.4.2.2.2. 10.4.2.2.2. By Neoantigen Type
10.4.2.2.3. 10.4.2.2.3. By Route of Administration
10.4.2.2.4. 10.4.2.2.4. By Cell
10.4.2.2.5. 10.4.2.2.5. By Technology
10.4.2.2.6. 10.4.2.2.6. By Application
15

• Table of Contents

S. No. Contents Contents Contents Contents Contents
10.4.3. UAE Neoantigen Cancer Vaccine Market Outlook UAE Neoantigen Cancer Vaccine Market Outlook UAE Neoantigen Cancer Vaccine Market Outlook
10.4.3.1. Market Size Forecast Market Size Forecast
10.4.3.1.1. By Value
10.4.3.2. Market Share Forecast Market Share Forecast
10.4.3.2.1. By Product
10.4.3.2.2. By Neoantigen Type
10.4.3.2.3. By Route of Administration
10.4.3.2.4. By Cell
10.4.3.2.5. By Technology
10.4.3.2.6. By Application
11. Market Dynamics Market Dynamics Market Dynamics Market Dynamics Market Dynamics
11.1. Drivers Drivers Drivers Drivers
11.2. Challenges Challenges Challenges Challenges
12. Market Trends and Developments Market Trends and Developments Market Trends and Developments Market Trends and Developments Market Trends and Developments
13. Competitive Landscape Competitive Landscape Competitive Landscape Competitive Landscape Competitive Landscape
13.1. Competition Outlook Competition Outlook Competition Outlook Competition Outlook
13.2. Players Profiled (Leading Companies) Players Profiled (Leading Companies) Players Profiled (Leading Companies) Players Profiled (Leading Companies)
13.2.1 OSE Immunotherapeutics SA OSE Immunotherapeutics SA OSE Immunotherapeutics SA
13.2.2. Gritstone bio, Inc. Gritstone bio, Inc. Gritstone bio, Inc.
13.2.3. BioNTech SE BioNTech SE BioNTech SE
13.2.4. F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd.
13.2.5. Pfizer Inc. Pfizer Inc. Pfizer Inc.
13.2.6. Merck Co. Inc. Merck Co. Inc. Merck Co. Inc.


16

• Table of Contents

S. No. Contents Contents Contents
13.2.7. Moderna, Inc. Moderna, Inc.
13.2.8. Avidea Technologies Inc. Avidea Technologies Inc.
13.2.9. Eli Lilly and Company Eli Lilly and Company
13.2.10. Vaccibody AS Vaccibody AS
13.2.11. Agenus Inc. Agenus Inc.
13.2.12. Novogene Co., Ltd. Novogene Co., Ltd.
13.2.13. ZIOPHARM Oncology Inc ZIOPHARM Oncology Inc
13.2.14. ISA Pharmaceuticals BV ISA Pharmaceuticals BV
13.2.15. BrightPath Biotherapeutics Co., Ltd. BrightPath Biotherapeutics Co., Ltd.
13.2.16. Vaximm AG Vaximm AG
13.2.17. Medigene AG Medigene AG
13.2.18. Genocea Biosciences Inc. Genocea Biosciences Inc.
13.2.19. Advaxis, Inc. Advaxis, Inc.
13.2.20. Nouscom AG Nouscom AG
14. Strategic Recommendations Strategic Recommendations Strategic Recommendations
15. About Us Disclaimer About Us Disclaimer About Us Disclaimer
17
PRODUCT OVERVIEW
18

• Scope of Report
• Product of Interest (POI) Neoantigen Cancer
  Vaccine

Neoantigens are tumor specific antigens produced
from mutated proteins which are only found in
specific cancer cells. Neoantigens are of two
subtypes Shared neoantigens, which are unique to
an individual or tumor type and personalized
neoantigens, which are highly specific to an
individuals tumor. Neoantigen cancer vaccine
activates the immune system to produce a
cytotoxic T-lymphocyte (CTL) which reacts against
neoantigen based tumor cell that helps to remove
cancer cells. Tumor vaccines that target
neoantigens mainly include nucleic acid,
dendritic cell (DC)-based vaccine, tumor cell and
synthetic-long peptide (SLP) vaccines. Currently,
several clinical trials have demonstrated the
safety and efficacy of these vaccines. The use of
neoantigens is a new approach to cancer
vaccines, which carry the exact mutations found
in the patients tumor. The key factors
responsible for the growth of global neoantigen
cancer vaccine market are rapid innovations in
technology as well as infrastructural
developments in healthcare sector.
Market Segmentation
PRODUCT
CELL
APPLICATION

• Melanoma
• Brain Cancer
• Gastrointestinal
• Lung
• Others

• Personalized Neoantigen Vaccine
• Off-the shelf Neoantigen Vaccine

• Autologous
• Allogenic

NEOANTIGEN TYPE

• Nucleic Acid
• Dendritic Cell
• Tumor Cell
• Synthetic Long Peptide (SLP)

ROUTE OF ADMINISTRATION
DELIVERY MECHANISM

• Intravenous
• Intramuscular
• Transdermal
• Others

• Gene Gun
• Electroporation
• Liposomes
• Virosomes
• Others

19
RESEARCH METHODOLOGY
20

• Research Methodology

Market Profiling
Data Analysis
Data Collection
Data Validation
Developing list of respondents
Formulating Questionnaire
In-depth secondary research was conducted to
determine top players in the global neoantigen
cancer vaccine market, overall market size and
segmental market size.
The data was scrutinized using MS-Excel,
statistical tools and internal proprietary
database to obtain qualitative and quantitative
insights about the global neoantigen cancer
vaccine market.
Data obtained as a result of primary and
secondary research was validated through rigorous
triangulation.
TechSci conducted interviews with industry
experts and industry players for data collection
and verification.
In order to conduct industry experts interviews,
TechSci formulated a detailed discussion guide.
List of industry players and industry specialists
was developed.
Primary Research
Desk Research
Company Analysis

• Recent Developments
• Market Changing Aspects/Dynamics
• Government Policies
• Conclusion

• Market Participants
• Key Strengths

• Identifying Key Opinion Leaders
• Questionnaire Design
• In-depth Interviews

21

• Research Methodology

• Baseline Methodology
• Our dedicated team of industry experts has
  monitored and analyzed various aspects of the
  global neoantigen cancer vaccine market. The team
  has analyzed the outlook of various segments of
  this market, while considering the major
  influencing factors. The study includes market
  forecasting, which would enable our clients to
  take better decisions while planning their
  strategy to achieve sustainability in global
  neoantigen cancer vaccine market. The market data
  for the historic years between 2016 and 2020 has
  not been covered in our report since currently
  there is no commercial launch of neoantigen
  cancer vaccine at the global, regional or
  country level and all the products are in
  clinical phase of development.
• Methodology Followed for Calculation of Market
  Size
• Market Size by Value Market size, in terms of
  value, for the forecast years was calculated
  based on information collected through exhaustive
  secondary research and primary surveys, with
  various key opinion leaders/stakeholders, such as
  neoantigen cancer vaccine companies, channel
  partners, market influencers industry experts
  and other industry participants.
• The team interviewed more than 15 neoantigen
  cancer vaccine companies and 15 20 Industry
  experts and other value chain stakeholders in the
  global neoantigen cancer vaccine market to obtain
  the overall market size during the forecast
  period, which was validated by the Delphi
  technique. Taking standard deviation into
  consideration, the market size was averaged out,
  to arrive at the market size data.

22

• Research Methodology

• Respondents were asked about the future market
  growth rates, market size by product, by
  neoantigen type, by route of administration, by
  cell, by technology, by delivery mechanism, by
  application, by company and by region. Removing
  the outlier responses, the geometric mean of
  growth estimates and companywise revenue shares
  projected across various segments were
  considered, to arrive at the final revenue
  shares. Revenue shares generated across various
  segments were further triangulated from responses
  received from the stakeholders.
• Methodology Followed for Calculation of Market
  Shares
• Market shares by product, by neoantigen type, by
  route of administration, by cell, by technology,
  by delivery mechanism, by application, by company
  and by region were calculated based on the
  responses received through primary surveys with
  industry experts, in which the respondents were
  asked about the market shares generated from
  various types of neoantigen cancer vaccine
  market. The final shares were calculated by
  taking the geometric mean of the responses
  gathered from key opinion leaders after
  eliminating the outliers.
• Methodology Followed for Forecasting
• TechSci Research performed periodical checks on
  data collected through the surveys with logic
  checks and analyzed the survey results in
  SPSS/Tableau Software.
• Data triangulation techniques were applied to
  fill the gaps and to present a more meaningful
  picture of the market. To forecast global
  neoantigen cancer vaccine market, TechSci
  Research used various forecast techniques such
  as
• Moving Average
• Time Series Analysis
• Regression Analysis
• Econometric and Judgmental Analysis

23

• Research Methodology

TechSci Research used its own forecast tool,
which is based on the growth of various allied
industries in respective regions. TechSci
Research also used the impact analysis during
short, medium and long term period to estimate
the demand and to reach accurate market numbers.
It should be noted that the figures compiled are
only for the organized market including market
share data. The currency used in the report is
the United States Dollar (USD), with the market
size indicated in USD million.
Partial List of Companies Interviewed Key Secondary Sources
Avidea Technologies Inc. F Hoffmann-La Roche Ltd. Agenus Inc. Nouscom AG Merck Co. Inc. Pfizer Inc. Advaxis Inc. Medigene AG Genocea Biosciences Inc. Gritstone Oncology Inc. OSE Immunotherapeutics SA Eli Lilly Co. Ltd. Novogene Co. Ltd. Moderna Inc. BioNTech SE ZIOPHARM Oncology Inc. ISA Pharmaceutical B.V. Vaccibody AS BrightPath Biotherapeutics Co., Ltd. Vaximm AG World Health Organization (WHO) American Association for Cancer Research (AACR) Society for Immunotherapy of Cancer National Cancer Institute (NCI) European Medicine Agency (EMA) World Bank TechSci Research Proprietary Database Knowledge Repository Company Annual Reports Industry Magazines Industry Reports News Dailies Credible Paid Databases
24

• Industry Brief

According to TechSci Research report, Global
Neoantigen Cancer Vaccine Market By Product
(Personalized neoantigen vaccine, Off-the shelf
neoantigen vaccine), By Neoantigen Type
(Synthetic long peptide (SLP), Nucleic Acid,
Dendritic Cell, Tumor Cell), By Route of
Administration (Intravenous, Intramuscular,
Transdermal, Others), By Cell (Autologous,
Allogenic), By Technology (RNA sequencing, Whole
genome sequencing, HLA typing), By Delivery
Mechanism (Liposomes, Virosomes, Electroporation,
Gene gun, Others), By Application (Lung,
Melanoma, Gastrointestinal, Brain Cancer,
Others), By Region, Competition, Forecast
Opportunities, 2026, global neoantigen cancer
vaccine market is expected to reach USD1754.44
million in 2026, growing with double-digit CAGR
of 54.18 during the forecast period. Neoantigen
cancer vaccines are the type of vaccines that
help to boost the immune system with the help of
single or several antigens. Surging prevalence
of cancer is one of the major factors accounting
for the growth of global neoantigen cancer
vaccine market. Moreover, rapid adoption of
personalized medicines for the patients
treatment on individual level is further expected
to aid in the growth of global neoantigen cancer
vaccine market through the forecast period. The
product type is segmented into personalized
neoantigen vaccine and off-the shelf neoantigen
vaccine. The personalized neoantigen vaccine is
expected to dominate the market in the forecast
period due to high number of clinical trials and
extensive RD for the development of personalized
neoantigen cancer vaccines. In addition to this,
continuous advancements in several drug delivery
technologies is anticipated to positively
influence the growth of the global neoantigen
cancer vaccine market in the years to come. Also,
increased funding for executing research and
development activities is making headway for the
growth of global neoantigen cancer vaccine market
across the globe. Along with this, expected
launch of first neoantigen vaccine Tedopi in the
market, is estimated to boost the market growth
through 2026. However, high cost of personalized
cancer vaccines as well as obstacles in clinical
development are the major factors that might
restrain the growth of the global neoantigen
cancer vaccine market through 2026. Global
neoantigen cancer vaccine market can be segmented
based on product, neoantigen type, route of
administration, cell, technology, delivery
mechanism, application, company, and region.
Considering the delivery mechanism, the market is
fragmented into liposomes, virosomes
electroporation, gene gun, and others. The
liposomes segment is anticipated to grow at the
high rate during the forecast period. In terms of
technology, the market is fragmented into RNA
sequencing, whole genome sequencing, and HLA
typing. Out of which, RNA sequencing technology
segment is forecast to register high growth in
the next 5 years on account of studying what
genes are mis regulated. OSE Immunotherapeutics
SA, Gritstone bio, Inc., BioNTech SE, F.
Hoffmann-La Roche Ltd., Pfizer Inc., Merck Co.,
Inc., Moderna Inc., Avidea Technologies, Inc.,
Eli Lilly and Company, Vaccibody AS, Agenus Inc.,
Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA
Pharmaceuticals B.V., BrightPath
Biotherapeutics Co., Ltd., Vaximm AG, Medigene
AG, Genocea Biosciences Inc., Advaxis, Inc.,
Nouscom AG among others are the leading players
operating in global neoantigen cancer vaccine
market. The leading players are adopting several
growth strategies to enhance the market scenario
of neoantigen cancer vaccine. Some of the
competitive strategies include partnerships,
collaborations, business expansions, as well as
mergers and acquisitions, partnership
opportunities in order to diverse their product
portfolio and to strengthen their market
position. North America is forecast to dominate
the global neoantigen cancer vaccine market with
a highest market share among all the regions
during the next five years on the account of the
existence of many key market players in this
region. Asia-Pacific is anticipated to register
high growth during the forecast period which can
be accredited to rising population that has
cancer and significant number of clinical trials
going on in China. Furthermore, mounting
investment in research activities and improvement
in healthcare technologies is expected to aid the
growth of neoantigen cancer vaccine market in the
region until 2026., said Mr. Karan Chechi,
Research Director with TechSci Research, a
research based global management consulting firm.
25

• Sample Data - Snapshot

Global Neoantigen Cancer Vaccine Market Size, By
Volume (Million Units), By Value (USD Million),
2020-2026F
North America Neoantigen Cancer Vaccine Market
Share, By Product, By Value, 2020-2026F
North America Neoantigen Cancer Vaccine Market
Share, By Product, By Value, 2020-2026F
26

• Report Ordering

• Report Name Global Neoantigen Cancer
  Vaccine Market
• FORECAST AND OPPORTUNITIES
• 2020 2026

License Type Price
Single User License 4900
Multi-User License 5900
Custom Research License 8900
To View Sample OR Purchase Report  
27
About Us Disclaimer
TechSci Research is a global market research and
consulting company with offices in the US, UK and
India. TechSci Research provides market research
reports in number of areas to organizations. The
company uses innovative business models that
focus on improving productivity, while ensuring
creation of high-quality reports. The proprietary
forecasting models use various analyses of both
industry-specific and macroeconomic variables on
a state-by-state basis to produce a unique
bottom-up model of a country, regional and
global industry prospects. Combined with the
detailed analysis of company activity and
industry trends, the result is a uniquely rich
evaluation of the opportunities available in the
market.
Related Reports

• Global Coronavirus Vaccine Market, By Infection
  Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven
  CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2, Others), By
  Vaccine Type (Inactivated Coronavirus Vaccine,
  Live Attenuated Coronavirus Vaccine, S-Protein
  Based Coronavirus Vaccine), By Product Type
  (Monovalent Vaccine v/s Multivariant Vaccine), By
  Route of Administration (Oral, Intramuscular,
  Subcutaneous), By Patient Type (Pediatric v/s
  Adult), By End User (Hospitals, Clinics, Research
  Institutes, Others), By Region, Forecast
  Opportunities, 2025
• Global Oncology Drugs Market, By Drug Type
  (Cytotoxic Drugs, Targeted Drugs, Hormonal
  Drugs), By Therapy (Chemotherapy, Targeted
  Therapy, Immunotherapy, Hormonal Therapy,
  Others), By Drug Therapy (Adjuvant, Neoadjuvant
  and Concurrent), By Route of Administration
  (Oral, Intravenous, Subcutaneous, Others), By
  Gender (Male, Female), By Cancer Type (Lung
  Cancer, Stomach Cancer, Others), By Distribution
  Channel (Hospital Pharmacies, Others), By Region,
  Competition, Forecast Opportunities, 2025

TechSci Research North America 708 Third
Avenue, Manhattan, New York, United States Tel
1- 646- 360- 1656 Email sales_at_techsciresearch.co
m www.techsciresearch.com
TechSci Research Europe 54, Old brook,
Bretton, Peterborough, United Kingdom Email
sales_at_techsciresearch.com www.techsciresearch.com
TechSci Research Asia-Pacific B 44, Sector
57, Noida, National Capital Region, U.P. -
India Tel [phone] Email
sales_at_techsciresearch.com www.techsciresearch.com
Disclaimer
The contents of this report are based on
information generally available to the public
from sources believed to be reliable. No
representation is made that it is timely,
accurate or complete. TechSci Research has taken
due care and caution in compilation of data as
this has been obtained from various sources
including which it considers reliable and first
hand. However, TechSci Research does not
guarantee the accuracy, adequacy or completeness
of any information and it is not responsible for
any errors or omissions or for the results
obtained from the use of such information and
especially states that it has no financial
liability whatsoever to the subscribers / users
of this report. The information herein, together
with all estimates and forecasts, can change
without notice. All the figures provided in this
document are indicative of relative market size
and are strictly for clients internal
consumption. Usage of the same for purpose other
than internal will require prior approval of
TechSci Research.